



# **Raymed Labs Ltd.**

*Manufacturers of Allopathic Medicines*

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :

GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

5<sup>th</sup> February, 2015

The Manager  
The Department of Corporate Services  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai – 400001

**BSE Scrip Code: 531207**

**Subject: Outcome of the Meeting of the Board of Directors**

Dear Sir:

This is to inform you that in the meeting of the Board of Directors held on Thursday, 5<sup>th</sup> February 2015, following resolutions were passed:

1. The Board considered and approved the Un-audited Financial Results for the quarter ended 31<sup>st</sup> December, 2014 as per Clause 41 of the listing Agreement.
2. The Board took note of the Limited Review for the Quarter as placed by the Auditor of the Company.
3. The Board considered and approved the Capital Reduction pursuant to the provisions of Companies Act, 1956 and Companies Act, 2013, wherever applicable and subject to the Shareholders approval and approval of Board/High Court/Tribunal.
4. The Board considered and approved the resignation of Mr. Ankur Arora from the directorship of the Company.


We hope you will find the same in order.

You are kindly requested to take the information on record.

Thanking you,

Sincerely,

For Raymed Labs Ltd.



**Ajai Goyal**  
Managing Director

DIN: 02636418

Encl: as stated

Cc: **Delhi Stock Exchange Limited**  
**Uttar Pradesh Stock Exchange Limited**  
**Ahmedabad Stock Exchange Limited**  
**Jaipur Stock Exchange Limited**

*Life is Precious .....and Raymed cares*



# Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :  
GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)  
e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com  
Tel. 0132-3242000

## Unaudited Financial Results for the Quarter Ended on December 31, 2014

PART I							Rs. in Lacs
	Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months Ended	Year to Date Figures for Current Period Ended	Year to Date Figures for Previous Year Ended	Previous Year Ended
		31-12-2014	30-09-2014	31-12-2013	31-12-2014	31-12-2013	31-03-2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-	-	-
	(b) Other Operating Income	-	-	-	-	-	-
	Total Income from Operations (net)	-	-	-	-	-	-
2	Expenses						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	Changes in inventories of finished goods,	-	-	-	-	-	-
	(c) work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee expenses & benefits	0.15	0.25	0.42	0.85	1.26	1.68
	(e) Depreciation and amortisation expense	-	-	-	-	0.31	0.19
	(f) Other expenses	0.16	2.17	0.15	2.56	1.14	1.52
	Total Expenses	0.31	2.42	0.57	3.41	2.71	3.39
3	Profit/(Loss) from Operations before other Income, Finance costs and Exceptional Items (1-2)	-0.31	-2.42	-0.57	-3.41	-2.71	-3.39
4	Other Income	0.54	0.54	-	1.62	1.59	2.13
5	Profit/Loss from ordinary activities before finance costs and exceptional Items (3+4)	0.23	-1.88	-0.57	-1.79	-1.12	-1.26
6	Finance Costs	-	-	-	-	-	-
7	Profit/Loss from ordinary activities after finance costs but before exceptional Items (5-6)	0.23	-1.88	-0.57	-1.79	-1.12	-1.26
8	Exceptional Items	-	-	-	-	0.17	3.66
9	Profit/Loss from Ordinary Activities before tax (7-8)	0.23	-1.88	-0.57	-1.79	-1.28	-4.92
10	Tax Expense	-	-	-	-	-	-
11	Net Profit/ Loss from Ordinary Activities after Tax (9-10)	0.23	-1.88	-0.57	-1.79	-1.28	-4.92
12	Extraordinary Item (net of tax expense)	-	-	-	-	-	-
13	Net Profit/ Loss for the period (11-12)	0.23	-1.88	-0.57	-1.79	-1.28	-4.92
17	Paid up Equity Share Capital (Face Value Rs.10/- per share)	427.35	427.35	427.35	427.35	427.35	427.35
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-
19 i	Earning Per Share (before extraordinary items)	0.005	-0.044	-0.01	-0.042	-0.03	-0.12
19 ii	Earning Per Share (after extraordinary items)	0.005	-0.044	-0.01	-0.042	-0.03	-0.12



*Life is Precious .....and Raymed cares*



# Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :

GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

PART II						
Particulars	3 Months Ended 31-12-2014	Preceding 3 Months Ended 30-09-2014	Corresponding 3 Months Ended 31-12-2013 in the Previous Year	Year to Date Figures for Current Period Ended 31-12-2014	Year to Date Figures for the Previous Year Ended 31-12-2013	Previous Year Ended 31-03-2014
<b>A PARTICULARS OF SHAREHOLDING</b>						
1 Public Shareholding						
- Number of shares	30,61,450	30,61,450	30,61,450	30,61,450	30,61,450	30,61,450
- Percentage of shareholding	71.64%	71.64%	71.64%	71.64%	71.64%	71.64%
2 Promoters and promoter group Shareholding						
a) Pledged/Encumbered						
- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a% of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b) Non-encumbered						
- Number of Shares	12,12,050	12,12,050	12,12,050	12,12,050	12,12,050	12,12,050
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a% of the total share capital of the company)	28.36%	28.36%	28.36%	28.36%	28.36%	28.36%
<b>B INVESTOR COMPLAINTS</b>						
	3 Months Ended (31/12/2014)					
Pending at the beginning of the quarter	NIL					
Received during the quarter	NIL					
Disposed of during the quarter	NIL					
Remaining unresolved at the end of the quarter	NIL					

Notes:

- The unaudited financial statements for the quarter ended on December 31, 2014 as reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 05, 2015. The information presented above is extracted from the financial statement.
- EPS has been calculated in accordance with AS-20 issued by ICAI.
- The Business of the Company falls under a single segment for the purpose of Accounting Standard As-17, issued by The Institute of Chartered Accountants of India.
- Previous period/year figures have been regrouped/rearranged, wherever found necessary.
- No investor complaints were pending in the beginning and end of the quarter ended December 2014.

For Raymed Labs Limited

*Ajal Goyal*

Ajal Goyal  
Director

Place: Saharanpur  
Date: 05-02-2015

*Life is Precious .....and Raymed cares*





# A. KAY. MEHRA & CO.

## CHARTERED ACCOUNTANTS

114 (Basement), Mall Road, Kingsway Camp,  
Delhi-110009 (Near GTB Nagar Metro Station)  
Tel No. : 011-32965997, 9891295255  
E-mail : akmca1969@gmail.com  
Website : [www.akmca.in](http://www.akmca.in)

### LIMITED REVIEW REPORT

To the Members of **RAYMED LABS LIMITED**

We have reviewed the accompanying statement of unaudited financial results of M/S **RAYMED LABS LIMITED** for the Quarter ended **31<sup>st</sup> December 2014** except for the disclosure regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' Which have been traced from disclosures made by management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2400 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an opinion.

Based on our review nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the Applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement with stock exchange including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s. A Kay Mehra & Co.  
Chartered Accountants

*Deepak Suneja*

(Deepak Suneja)  
(Partner)  
(Membership No. 501957)



Place : New Delhi  
Date : February 05, 2015